Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Zymeworks (ZYME) EBIAT (2021 - 2025)

Zymeworks' EBIAT history spans 5 years, with the latest figure at -$41.2 million for Q4 2025.

  • On a quarterly basis, EBIAT fell 75.31% to -$41.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$81.1 million, a 33.88% increase, with the full-year FY2025 number at -$81.1 million, up 33.88% from a year prior.
  • EBIAT hit -$41.2 million in Q4 2025 for Zymeworks, down from -$19.6 million in the prior quarter.
  • Over the last five years, EBIAT for ZYME hit a ceiling of $309.4 million in Q4 2022 and a floor of -$72.6 million in Q1 2022.
  • Historically, EBIAT has averaged -$16.5 million across 5 years, with a median of -$30.8 million in 2024.
  • Biggest five-year swings in EBIAT: skyrocketed 890.33% in 2022 and later plummeted 104.68% in 2023.
  • Tracing ZYME's EBIAT over 5 years: stood at -$39.2 million in 2021, then skyrocketed by 890.33% to $309.4 million in 2022, then plummeted by 104.68% to -$14.5 million in 2023, then crashed by 62.31% to -$23.5 million in 2024, then tumbled by 75.31% to -$41.2 million in 2025.
  • Business Quant data shows EBIAT for ZYME at -$41.2 million in Q4 2025, -$19.6 million in Q3 2025, and $2.3 million in Q2 2025.